Study of cabozantinib in advanced kidney cancer patients
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial looks at how well cabozantinib works in people with advanced kidney cancer that has spread. It focuses on patients who had a quick response or a long response to the drug.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced kidney cancer (clear cell type) that has spread.
- You have a tumor sample from the past 5 years available for testing.
- You were treated with cabozantinib after at least one other therapy.
- Your cancer got worse within 3 months or after 9 months of starting cabozantinib.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests a different dosing schedule of cabozantinib (a cancer medicine) for metastatic kidney cancer and certain neuroendocrine tumors. It aims to see if the timing and schedule can work well for people with advanced disease.
This trial tests a new combination of two oral drugs (abemaciclib and cabozantinib) for people with advanced kidney cancer (clear cell type) who have already tried at least two other treatments, including an immunotherapy and a targeted therapy, but their cancer kept growing. The goal is to see if this combination can shrink tumors or slow the cancer.
This trial tests whether tracking your symptoms with a digital app can help manage side effects while you receive two medications (cabozantinib and nivolumab) for advanced clear-cell kidney cancer that hasn't been treated before.
This trial tests a new drug, PF-08634404, alone or with other cancer treatments, for adults with advanced kidney cancer that has not been treated before. It aims to see if the drug can help shrink tumors or stop them from growing.
This trial studies how well cabozantinib works for advanced kidney cancer in people who are already receiving hemodialysis. It aims to see whether the treatment is effective and safe for this specific kidney function group.
This Phase 2 study tests a “next-step” cabozantinib strategy for advanced kidney cancer (RCC) after your cancer previously responded to cabozantinib and then progressed. It aims to see if re-using cabozantinib in a planned sequence can control the cancer again with manageable side effects.
Hear when a new Metastatic Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.